Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine.
Abáigar M, Ramos F, Benito R, Díez-Campelo M, Sánchez-del-Real J, Hermosín L, Rodríguez JN, Aguilar C, Recio I, Alonso JM, de las Heras N, Megido M, Fuertes M, del Cañizo MC, Hernández-Rivas JM. Abáigar M, et al. Among authors: hermosin l. Ann Hematol. 2013 Nov;92(11):1543-52. doi: 10.1007/s00277-013-1799-9. Epub 2013 Jun 6. Ann Hematol. 2013. PMID: 23740492
Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
Abáigar M, Robledo C, Benito R, Ramos F, Díez-Campelo M, Hermosín L, Sánchez-Del-Real J, Alonso JM, Cuello R, Megido M, Rodríguez JN, Martín-Núñez G, Aguilar C, Vargas M, Martín AA, García JL, Kohlmann A, Del Cañizo MC, Hernández-Rivas JM. Abáigar M, et al. Among authors: hermosin l. PLoS One. 2016 Oct 14;11(10):e0164370. doi: 10.1371/journal.pone.0164370. eCollection 2016. PLoS One. 2016. PMID: 27741277 Free PMC article.
Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.
Sanchez-Garcia J, Falantes J, Medina Perez A, Hernandez-Mohedo F, Hermosin L, Torres-Sabariego A, Bailen A, Hernandez-Sanchez JM, Solé Rodriguez M, Casaño FJ, Calderon C, Labrador M, Vahí M, Serrano J, Lumbreras E, Hernández-Rivas JM; Grupo Andaluz SMD. Sanchez-Garcia J, et al. Among authors: hermosin l. Leuk Lymphoma. 2018 May;59(5):1095-1104. doi: 10.1080/10428194.2017.1366998. Epub 2017 Aug 24. Leuk Lymphoma. 2018. PMID: 28836866 Clinical Trial.
Genome-Wide DNA Copy Number Analysis of Acute Lymphoblastic Leukemia Identifies New Genetic Markers Associated with Clinical Outcome.
Forero-Castro M, Robledo C, Benito R, Abáigar M, África Martín A, Arefi M, Fuster JL, de Las Heras N, Rodríguez JN, Quintero J, Riesco S, Hermosín L, de la Fuente I, Recio I, Ribera J, Labrador J, Alonso JM, Olivier C, Sierra M, Megido M, Corchete-Sánchez LA, Ciudad Pizarro J, García JL, Ribera JM, Hernández-Rivas JM. Forero-Castro M, et al. Among authors: hermosin l. PLoS One. 2016 Feb 12;11(2):e0148972. doi: 10.1371/journal.pone.0148972. eCollection 2016. PLoS One. 2016. PMID: 26872047 Free PMC article.
Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M, Robledo C, Benito R, Bodega-Mayor I, Rapado I, Hernández-Sánchez M, Abáigar M, Maria Hernández-Sánchez J, Quijada-Álamo M, María Sánchez-Pina J, Sala-Valdés M, Araujo-Silva F, Kohlmann A, Luis Fuster J, Arefi M, de Las Heras N, Riesco S, Rodríguez JN, Hermosín L, Ribera J, Camos Guijosa M, Ramírez M, de Heredia Rubio CD, Barragán E, Martínez J, Ribera JM, Fernández-Ruiz E, Hernández-Rivas JM. Forero-Castro M, et al. Among authors: hermosin l. Br J Cancer. 2017 Jul 11;117(2):256-265. doi: 10.1038/bjc.2017.152. Epub 2017 May 30. Br J Cancer. 2017. PMID: 28557976 Free PMC article.
Next-Generation DNA Sequencing-Based Gene Panel for Diagnosis and Genetic Risk Stratification in Onco-Hematology.
Gargallo P, Molero M, Bilbao C, Stuckey R, Carrillo-Cruz E, Hermosín L, Pérez-López O, Jiménez-Velasco A, Soria E, Lázaro M, Carbonell P, Yáñez Y, Gómez I, Izquierdo-García M, Valero-García J, Ruiz C, Such E, Calabria I. Gargallo P, et al. Among authors: hermosin l. Cancers (Basel). 2022 Apr 14;14(8):1986. doi: 10.3390/cancers14081986. Cancers (Basel). 2022. PMID: 35454892 Free PMC article.
Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa.
Roman-Gomez J, Castillejo JA, Jimenez A, Cervantes F, Boque C, Hermosin L, Leon A, Grañena A, Colomer D, Heiniger A, Torres A. Roman-Gomez J, et al. Among authors: hermosin l. J Clin Oncol. 2003 Apr 15;21(8):1472-9. doi: 10.1200/JCO.2003.08.166. J Clin Oncol. 2003. PMID: 12697869
Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology.
Martínez-Laperche C, Kwon M, Franco-Villegas AC, Chillón MC, Castro N, Anguita E, Dolz S, Rodríguez-Medina C, Hermosín L, Bellón JM, Prieto-Conde MI, Barragán E, Gómez-Casares M, Ayala R, Martínez-López J, González-Díaz M, Díez-Martin JL, Buño I; Cooperative Group for Molecular Biology in Haematology (GBMH). Martínez-Laperche C, et al. Among authors: hermosin l. Br J Haematol. 2018 May;181(4):542-546. doi: 10.1111/bjh.14635. Epub 2017 Apr 3. Br J Haematol. 2018. PMID: 28369773 Free article. No abstract available.
16 results